THE INTRACELLULAR AND CIRCULATING POOLS OF PROTEASOMES: THE VALUE AT CANCER IN DIFFERENT LOCATIONS
Abstract
This review presents the structure of the proteasome system, discusses its involvement in the pathogenesis of many cancers, including the process of metastasis. It describes the distinctive structural characteristics of intra- and extracellular pools of proteasomes, possible ways of their exit into the extracellular space and their forms of existence outside the cell. Also in the present review discusses the importance of circulating proteasomes for prognosis course of the cancer.
About the Authors
E. E. Shashova
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Shashova Elena Evgenievna, MD, PhD, Senior Researcher, Tumor Biochemistry Laboratory.
E-mail: SchaschovaEE@oncology.tomsk.ru. SPIN-code: 5079-8784.E. S. Kolegova
Tomsk Cancer Research Institute;
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
Kolegova Elena Sergeevna, assistant researcher, Tumor Biochemistry Laboratory.
E-mail: elenakolegova@oncology.tomsk.ru. SPIN-code: 5865-1264.
I. V. Kondakova
Tomsk Cancer Research Institute
Russian Federation
Russian Federation
Kondakova Irina Viktorovna, MD, Professor, Tumor Biochemistry Laboratory.
Phone: +7 3822 51-25-29. E-mail: kondakova@oncology.tomsk.ru. SPIN-code: 9338-4149
A. A. Zavyalov
Tomsk Cancer Research Institute;
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
Zavyalov Alexandr Alexandrovich, MD, DSc, Principal Researcher, Thoracic and Abdominal Department.
E-mail: ZavyalovAA@oncology.tomsk.ru. SPIN-code: 5087-2394.
References
1. Zaikova Y.Y., Kulichkova V.A., Ermolaeva Y.B., Barlev N.A., Tsimokha A.S., Bottrill A. Characterisation of extracellular proteasomes and its interacting proteins by ITRAQ – massspectrometry // Citologija. 2013. № 3. P. 111–122. [in Russian]
2. Zajkova Ju.Ja., Kulichkova V.A., Ermolaeva Ju.B., Gauze L.N., Cimoha A.S. The comparative analysis of extra- and intracellular proteasomes from K562 cell line // Citologija. 2011. № 6. P. 459–465. [in Russian]
3. Ivanova Je.V., Kondakova I.V., Cheremisina O.V., Afanas'ev S.G. Role of ubiquitin proteasome system in gastric cancer pathogenesis // Sibirskij onkologicheskij zhurnal. 2014. № 5. P. 64–71. [in Russian]
4. Kondakova I.V., Junusova N.V., Spirina L.V., Kolomiec L.A., Villert A.B. Association between intracellular proteinase activities and the content of locomotor proteins in tissues of primary tumors and metastases of ovarian cancer // Russian Journal of Bioorganic Chemistry. 2014. Vol. 40 (6). P. 735–742. [in Russian]
5. Kondakova I.V., Kakurina G.V., Spirina L.V., Cheremisina O.V., Pankova O.V., Men’shikov K.Ju. Assessment of extracellular and intracellular proteolysis in pretumor and tumor diseases of the larynx // Sibirskij onkologicheskij zhurnal. 2014. № 3. P. 45–50. [in Russian]
6. Kakurina G.V., Kondakova I.V., Chojnzonov E.L. Prognosis for the metastasis of squamous cell carcinoma of the head and neck // Voprosy onkologii. 2012. Vol. 58 (1). P. 26–32. [in Russian]
7. Spirina L.V., Kondakova I.V. The role of specific intracellular proteolysis in oncogenesis // Voprosy onkologii. 2008. Vol. 54 (6). P. 690–694. [in Russian]
8. Spirina L.V., Kondakova I.V., Usynin Y.A., Kolomiets L.A., Vintizenko S.I., Bochkareva N.V. Proteasome activity and groath factors expression in kidney, bladder and endometrial cancers // Rossiyskiy onkologicheskiy zhurnal. № 1. P. 23–25. [in Russian]
9. Spirina L.V., Kondakova I.V., Usynin E.A., Kolomiec L.A., Choinzonov E.L., Mukhamedov M.R., Chernyshova A.L., Sharova N.P. Proteasome activity in cancer tissues // Sibirskij onkologicheskij zhurnal. 2009. № 5. P. 49–52. [in Russian]
10. Sorokin A.V., Kim E.R., Ovchinnikov L.P. Proteasome system of protein degradation and processing // Uspehi biologicheskoj himii. Vol. 49. P. 3–76. [in Russian].
11. Chojnzonov E.L., Spirina L.V., Kondakova I.V., Chizhevskaja S.Ju., Shishkin D.A., Kul’bakin D.E. Prognostic value of proteasome activity determination in squamous cell carcinomas of head and neck // Sibirskij nauchnyj medicinskij zhurnal. 2014. Vol. 34 (4). P. 103–108. [in Russian]
12. Sharova N.P., Sumedi I.R., Astakhova T.M., Plekhanova A.S., Liupina Iu.V., Shashova E.E., Kondakova I.V., Rodoman G.V. Diagnostics of thyroid cancer: limitations of the existing methods and perspectives for future developments // Izv. Akad. Nauk. Ser. Biol. 2014. № 4. P. 348–354. [in Russian]
13. Shashova E.E., Spirina L.V., Kondakova I.V., Slonimskaja E.M., Kolomiec L.A., Chernyshova A.L., Glushhenko S.A., Savenkova O.V. The association of proteasome activity and subunits composition with estrogen and progesterone receptors expression in breast аnd endometrial cancers // Molekuljarnaja medicina. 2014. № 3. P. 51–56. [in Russian]
14. Shashova E.E., Kondakova I.V., Slonimskaja E.M., Glushhenko S.A., Kolegova E.S. Chymotrypsin-like and caspase-like proteasome activities in breast cancer // Sibirskij onkologicheskij zhurnal. 2013. № 5. P. 45–49. [in Russian]
15. Shashova E.E., Kondakova I.V., Slonimskaja E.M., Glushhenko S.A. Comparative study of the levels of estrogen and progesteron receptors in normal, tumor and metastatic tissues of breast cancer patients // Sibirskij onkologicheskij zhurnal. 2008. № 4. P. 42–45. [in Russian]
16. Shtamm T.A., Naryzhnyj S.N., Landa S.B., Burdakov V.S.,Artamonova T.O., Filatov M.V. Isolation and proteomic analysis of exosomes secreted by human cancer cells in vitro // Citologija. 2012. Vol. 54 (5). P. 430–438. [in Russian]
17. Junusova N.V., Spirina L.V., Kondakova I.V., Kolomiets L.A., Villert A.B., Shpileva O.V. Expression and activity of proteases in metastasis of ovarian cancer // Izv. Akad. Nauk. Ser. Biol. 2014. № 5. P. 448–455. [in Russian]
18. Junusova N.V., Kondakova I.V., Kolomiec L.A., Molchanov S.V. Proteasomes and exosomes in ovarian cancer: relation with disease prognosis and clinical outcome // Sibirskij onkologicheskij zhurnal. 2014. № 4. P. 53–59. [in Russian]
19. Bonella F., Sixt S.U., Thomassen J., Schmidt M., Cai M., Mori T., Guzman J., Costabel U. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis // Immunobiology. 2015. Vol. 220 (3). P. 382–388. doi: 10.1016/j.imbio.2014.10.010.
20. Broussas M., Dupont J., Gonzalez A., Blaecke A., Fournier M., Corvaïa N., Goetsch L. Molecular mechanisms, involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor // Int. J. Cancer. 2009. Vol. 124 (10). P. 2281–2293. doi: 10.1002/ijc.24186.
21. Bochman I., Ebstein F.,Lehman A.,Wohlschlager J., Sixt S.U., Kloetzel P.-M., Dahlman B. T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes // J. Cell. Mol. Med. 2014. Vol. 18 (1). P. 59–68. doi: 10.1111/jcmm.12160.
22. Bureau J.P., Olink-Coux M., Brouard N., Bayle-Julien S., Huesca M., Herzberg M., Scherrer K. Characterization of prosomes in human lymphocyte subpopulations and their presence as surface antigens // Exp. Cell Res. 1997. Vol. 231 (1). P. 50–60.
23. Egerer K., Kuckelkorn U., Rudolph P.E., Ruckert J.C., Dorner T., Burmester G.-R., Kloetzel P.-M., Feist E. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases // J. Rheumatol. 2002. Vol. 29 (10). P. 2045–2052.
24. Hoffmann O., Heubner M., Anlasik T., Winterhalter M., Dahlmann B., Kasimir-Bauer S., Kimmig R., Wohlschlager J., Sixt S.U. Circulating 20S proteasome in patients with non-metastasized breast cancer // Anticancer Res. 2011. Vol. 31 (6). P. 2197–2201.
25. Heubner M., Wimberger P., Dahlmann B., Kasimir-Bauer S., Kimmig R., Peters J., Wohlschlaeger J., Sixt S.U. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer // Gynecol. Oncol. 2011. Vol. 120 (2). P. 233–238. doi: 10.1016/j.ygyno.2010.10.014.
26. Jung T., Grune T. Structure of the proteasome // Prog. Mol. Biol. Transl. Sci. 2012. Vol. 109. P. 1–39. doi: 10.1016/B978-0-12-397863-9.00001-8.
27. Kitagawa K., Kotake Y., Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products // Cancer Science. 2009. Vol. 100 (8). P. 1374–1381. doi: 10.1111/j.1349-7006.2009.01196.x.
28. Kondakova I.V., Spirina L.V., Koval V.D., Shashova E.E., Choinzonov E.L., Ivanova E.V., Kolomiets L.A., Chernyshova A.L., Slonimskaya E.M., Usynin E.A., Afanas’ev S.G. Chymotrypsin-like activity and subunit composition of proteasomes in human cancers // Mol. Biol. 2014. Vol. 48 (3). P. 384–389.
29. Keller S., Konig A.-K., Marme F., Runz S., Wolterink S., Koensgen D., Mustea A., Sehouli J., Altevogt P. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes // Cancer Lett. 2009. Vol. 278 (1). P. 73–81. doi: 10.1016/j.canlet.2008.12.028.
30. Lavabre-Bertrand T., Henry L., Carillo S., Guiraud I., Quali A., Dutaud D., Laurent Aubry L., Jean-François Rossi J.-F., Bureau J.P. Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies // Cancer. 2001. Vol. 92 (10). P. 2493–2500.
31. Lai R.C., Tan S.S., Teh B.J., Sze S.K., Arslan F., de Kleijn D.P., Choo A., Lim S.K. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome // Int. J. Proteomics. 2012;2012:971907. doi: 10.1155/2012/971907.
32. Mani A., Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer // J. Clin. Oncol. 2005. Vol. 23 (21). P. 4776–4789.
33. Ma W., Kantarjian H., Bekele B., Donahue A.C., Zhang X., Zhang Z.J., O’Brien S., Elihu Estey E., Estrov Z., Cortes J., Keating M., Giles F., Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome // Clin. Cancer Res. 2009. Vol. 15 (11). P. 3820–3826. doi: 10.1158/1078-0432.CCR-08-3034.
34. Newman R.H., Whitehead P., Lally J., Coffer A., Freemont P. 20S human proteasomes bind with a specific orientation to lipid monolayers in vitro // Biochim. Biophys. Acta. 1996. Vol. 1281 (1). P. 111–116.
35. Ogawa S., Shih L.-Y., Suzuki T., Otsu M., Nakauchi H., Koeffler H.P., Sanada M. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms // Clin. Cancer Res. 2010. Vol. 16 (15). P. 3825–3831. doi: 10.1158/1078-0432.CCR-09-2341.
36. Powers G.L., Ellison-Zelski S.J., Casa A.J., Lee A.V., Alarid E.T. Proteasome inhibition represses ER gene expression in ER+ cells – a new link between proteasome activity and rstrogen signaling in breast cancer // Oncogene. 2010. Vol. 29 (10). P. 1509–1518. doi: 10.1038/onc.2009.434.
37. Rupp A.-K., Rupp C., Keller S., Brase J.C., Ehehalt R., Fogel M., Moldenhauer G., Marmé F., Sültmann H., Altevogt P. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage // Gynecol. Oncol. 2011. Vol. 122 (2). P. 437–446. doi: 10.1016/j.ygyno.2011.04.035.
38. Roth G.A., Moser B., Krenn C., Roth-Walter F., Hetz H., Richter S., Brunner M., Jensen-Jarolim E., Wolner E., Hoetzenecker K., Boltz- Nitulescu G., Ankersmit H.J. Heightened levels of circulating 20 S proteosome in critically ill patients // Eur. J. Clin. Invest. 2005. Vol. 35 (6). P. 399–403.
39. Rivett A.J., Palmer A., Knecht E. Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells // J. Histochem. Cytochem. 1992. Vol. 40 (8). P. 1165–1172.
40. Sixt S.U., Costabel U., Bonella F., Grunert K., Alami R., Hakenbeck J., Bauer P., Dahlmann B., Schmid K.W., Peters J., Wohlschlaeger J. Alveolar and intraparenchymal proteasome in sarcoidosis // Respir. Med. 2014. Vol. 108 (10). P. 1534–1541. doi: 10.1016/j.rmed.2014.09.004.
41. Schliessmann S.S., Cicko S., Thomassen J., Anlasik T., Müller T., Idzko M., Zissel G., Sixt S.U. Acute smoke exposure decreases bronchial extracellular proteasome concentration // Eur. Respir. J. 2011. Vol. 38. P. 737.
42. Shashova E.E., Lyupina Yu.V., Glushchenko S.A., Slonimskaya E.M., Savenkova O.V., Kulikov A.M., Gornostaev N.G., Kondakova I.V., Sharova N. Proteasome functioning in breast cancer: connection with clinicalpathological factors // PLoS ONE. 2014. Vol. 9 (10). E. 109933. doi: 10.1371/journal.pone.0109933.
43. Shashova E.E., Astakhova T.M., Plekhanova A.S., Bogomyagkova Y.V., Lyupina Y.V., Sumedi I.R., Slonimskaya E.M., Erokhov P.A., Abramova E.B., Rodoman G.V., Kuznetsov N.A., Kondakova I.V., Sharova N.P., Choinzonov E.L. Changes in proteasome chymotrypsin-like activity during the development of human mammary and thyroid carcinomas // Bull Exp Biol Med. 2013. Vol. 156 (2). P. 242–244.
44. Scheffler S., Kuckelkorn U., Egerer K., Dörner T., Reiter K., Soza A., Burmester G.R., Feist E. Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i) // Rheumatology. 2008. Vol. 47 (5). P. 622–626. doi: 10.1093/rheumatology/ken042.
45. Sixt S.U., Beiderlinden M., Jennissen H.P., Peters J. Extracellular proteasome in the human alveolar space: a new housekeeping enzyme? // Am. J. Physiol. Lung Cell Mol. Physiol. 2007. 292 (2). L. 1280–1288.
46. Sixt S.U., Alami R., Hakenbeck J., Adamzik M., Kloß A., Costabel U., Jungblut P. R., Dahlmann B., Peters J. Distinct proteasome subpopulations in the alveolar space of patients with the acute respiratory distress syndrome // Mediators Inflamm. 2012;2012:204250. doi: 10.1155/2012/204250.
47. Stoebner P.E., Lavabre-Bertrand T., Henry L., Guiraud I., Carillo S., Dandurand M. High plasma proteasome levels are detected in patients with metastatic malignant melanoma // Br. J. Dermatol. 2005. Vol. 152 (5). P. 948–953.
48. Tang K., Liu J., Yang Z., Zhang B., Zhang H., Huang C., Ma J., Shen G.X., Ye D., Huang B. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis // Biochem. Biophys. Res. Commun. 2010. Vol. 400 (3). P. 432–436 doi: 10.1016/j.bbrc.2010.08.095.
49. Wada M., Kosaka M., Saito S., Sano T., Tanaka K., Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance // J. Lab. Clin. Med. 1993. Vol. 121 (2). P. 215–223.
50. Xie Y. Structure, Assembly and Homeostatic Regulation of the 26S Proteasome // J. Mol. Cell Biol. 2010. Vol. 2 (6). P. 308–317. doi: 10.1093/jmcb/mjq030.
51. Yuan A., Farber E.L., Rapoport A.L., Tejada D., Deniskin R., Akhmedov N.B., Farber D.B. Transfer of microRNAs by embryonic stem cell microvesicles // PLoS One. 2009. Vol. 4 (3). E. 4722. doi: 10.1371/journal.pone.0004722.
52. Zhang J., Wu P., Hu Y. Clinical and marketed proteasome inhibitors for cancer treatment // Curr. Med. Chem. 2013. Vol. 20 (20). P. 2537–2551.
53. Zhang P.J., Zhao J., Li H.Y., Man J.H., He K., Zhou T., Pan X., Li A.L., Gong W.L., Jin B.F., Xia Q., Yu M., Shen B.F., Zhang X.M. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome // EMBO J. 2007. Vol. 26 (7). P. 1831–1842.
54. Zoeger A., Blau M., Egere K., Feist E., Dahlmann B. Circulating proteasome are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells // Clin. Chem. 2006. Vol. 52 (11). P. 2079–2086.
Review
For citations:
Shashova E.E., Kolegova E.S., Kondakova I.V., Zavyalov A.A. THE INTRACELLULAR AND CIRCULATING POOLS OF PROTEASOMES: THE VALUE AT CANCER IN DIFFERENT LOCATIONS. Siberian journal of oncology. 2015;(6):76-82. (In Russ.)
Views:
575
Email this article 
